Format

Send to

Choose Destination
Oncotarget. 2017 Apr 4;8(14):23760-23774. doi: 10.18632/oncotarget.15863.

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.

Author information

1
Former Affiliation: Department of Molecular Genome Analysis, German Cancer Research Center (DKFZ), 69118 Heidelberg, Germany.
2
Institute for Comparative Molecular Endocrinology, Ulm University, 89081 Ulm, Germany.
3
Institute for Laser Technologies in Medicine and Metrology, Ulm University, 89081 Ulm, Germany.
4
Former Affiliation: Lundbeckfonden Center of Excellence NanoCAN, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
5
Former Affiliation: Molecular Oncology, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
6
Department of Otorhinolaryngology, Section for Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen, 91054 Erlangen, Germany.
7
Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), 69118 Heidelberg, Germany.
8
Department of Biotechnology, Mannheim University of Applied Sciences, 68163 Mannheim, Germany.
9
Department of Dermatology, University Hospital Duisburg-Essen, 45147 Essen, Germany and German Cancer Consortium, 69118 Heidelberg, Germany.
10
Department of Clinical Genetics, Odense University Hospital, 5000 Odense, Denmark.
11
Lundbeckfonden Center of Excellence NanoCAN, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
12
Molecular Oncology, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.

Abstract

Next-generation sequencing has dramatically increased genome-wide profiling options and conceptually initiates the possibility for personalized cancer therapy. State-of-the-art sequencing studies yield large candidate gene sets comprising dozens or hundreds of mutated genes. However, few technologies are available for the systematic downstream evaluation of these results to identify novel starting points of future cancer therapies.We improved and extended a site-specific recombination-based system for systematic analysis of the individual functions of a large number of candidate genes. This was facilitated by a novel system for the construction of isogenic constitutive and inducible gain- and loss-of-function cell lines. Additionally, we demonstrate the construction of isogenic cell lines with combinations of the traits for advanced functional in vitro analyses. In a proof-of-concept experiment, a library of 108 isogenic melanoma cell lines was constructed and 8 genes were identified that significantly reduced viability in a discovery screen and in an independent validation screen. Here, we demonstrate the broad applicability of this recombination-based method and we proved its potential to identify new drug targets via the identification of the tumor suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with BRAF V600E mutations and high DUSP6 expression.

KEYWORDS:

cancer; functional genomics; isogenic cell line libraries; melanoma; synthetic lethal

PMID:
28423600
PMCID:
PMC5410342
DOI:
10.18632/oncotarget.15863
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center